Stem cell therapeutic agent for treating lower limb ischemic disease and use thereof

A technology for ischemic diseases and cell therapy, applied in cardiovascular system diseases, animal cells, cell dissociation methods, etc., can solve problems such as insufficient biological effects

Active Publication Date: 2021-07-06
BOYALIFE
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when it is applied clinically, it needs to face many technical problems such as insufficient biological effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0186] Embodiment 1, the composition of placenta MSC

[0187] The ingredient ratio (concentration) of the final product: mesenchymal stem cells, 4×10 7 pc / mL; phosphatidylserine, 0.2%; sodium chloride, 0.9%; water for injection, the balance.

[0188] Preparation method: refer to the method described in Examples 1-2 of CN102586184A (2012100446386) to obtain mesenchymal stem cells from placenta. Weigh phosphatidylserine and sodium chloride, add an appropriate amount of water for injection to dissolve, autoclave at 121°C for 15 minutes, and cool for later use; mix the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, and add water to the full amount , after mixing evenly, dispense into pre-filled syringes, ready to serve. It can be stored in a -80°C refrigerator for clinical application.

Embodiment 2

[0189] Embodiment 2, the composition of placenta MSC

[0190] The ingredient ratio (concentration) of the final product: mesenchymal stem cells, 2×10 7 pc / mL; phosphatidylserine, 0.3%; sodium chloride, 0.8%; water for injection, the balance.

[0191] Preparation method: refer to the method described in Examples 1-2 of CN102586184A (2012100446386) to obtain mesenchymal stem cells from placenta. Weigh phosphatidylserine and sodium chloride, add an appropriate amount of water for injection to dissolve, autoclave at 121°C for 15 minutes, and cool for later use; mix the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, and add water to the full amount , after mixing evenly, dispense into pre-filled syringes, ready to serve. It can be stored in a -80°C refrigerator for clinical application.

Embodiment 3

[0192] Embodiment 3, the composition of placenta MSC

[0193] The ingredient ratio (concentration) of the final product: mesenchymal stem cells, 5×10 7 pc / mL; phosphatidylserine, 0.1%; sodium chloride, 1.0%; water for injection, the rest.

[0194] Preparation method: refer to the method described in Examples 1-2 of CN102586184A (2012100446386) to obtain mesenchymal stem cells from placenta. Weigh phosphatidylserine and sodium chloride, add an appropriate amount of water for injection to dissolve, autoclave at 121°C for 15 minutes, and cool for later use; mix the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, and add water to the full amount , after mixing evenly, dispense into pre-filled syringes, ready to serve. It can be stored in a -80°C refrigerator for clinical application.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a stem cell therapeutic agent for treating lower extremity ischemic diseases and its use. One aspect relates to the use of a cell therapy composition in the preparation of a medicament for treating lower extremity ischemic diseases, the cell therapy composition comprising: umbilical cord mesenchymal stem cells, sodium chloride, and water. Another aspect relates to a cell therapy composition comprising the following components: umbilical cord mesenchymal stem cells, sodium chloride, and water. The preparation method of the cell therapy composition is as follows: adding materials such as sodium chloride into water to dissolve, optionally sterilizing the solution to obtain a matrix of the preparation; suspending the pre-prepared mesenchymal stem cells in the matrix, Pack and get it. The method of the present invention exhibits excellent technical effects as described in the specification. For example, the composition obtained by the present invention exhibits excellent cell resuscitation performance during cell resuscitation, and the viability of cells undergoing resuscitation process and the survival stability of cells after resuscitation are significantly higher than those of the present invention. There are technical solutions.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, relates to a stem cell therapeutic agent for treating and / or preventing acute and / or chronic lower limb ischemic diseases, and also relates to the use of the stem cell therapeutic agent for treating and / or preventing acute and / or chronic lower limb ischemia The use of the disease, and the method involving the use of the stem cell therapeutic agent for treating and / or preventing acute and / or chronic lower limb ischemic diseases. In particular, it relates to methods and compositions for treating ischemic diseases of the lower limbs using stem cells. Background technique [0002] Ischemic disease of lower extremities is a common disease that seriously affects patients' quality of life, limb survival and even life-threatening. Ischemic disease of the lower extremities refers to a class of diseases in which arterial stenosis or occlusion of the lower extremities and insufficient blood perfusion a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/0775
CPCA61K9/10A61K35/28A61K47/02A61K47/183A61K47/24A61P9/10C12N5/0665C12N2509/00
Inventor 肖海蓉许晓椿刘冰
Owner BOYALIFE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap